The Status of Biomarker Research in Low-Grade Gliomas

In an interview with Targeted Oncology, Alexander Helfand, MD discussed the current standard practice for testing patients with renal cell carcinoma and administering immunotherapy or targeted therapy.

In most key prespecified molecularly defined subsets of patients with pretreated KRAS G12C–mutated non–small cell lung cancer, sotorasib continued to demonstrate consistent benefit vs docetaxel.

In an interview with Targeted Oncology, Joshua K. Sabari, MD, discussed drug shortages and how they are affecting clinicians and patients in the oncology space.

In a phase 1 study, anti-tumor responses were induced with PRT811 treatment in patients with recurrent, high-grade glioma and advanced or metastatic uveal melanoma.

New data show the promise for use of tovorafenib to reduce pre-treated pediatric patients with a low-grade glioma.

The results of vorasidenib signal potential for the agent to become the first targeted therapy in low-grade glioma.